Thermo Fisher Scientific and Siemens join forces in PAT technology

MADISON, Wisc., April 6,  - Thermo Fisher Scientific Inc. has combined the Thermo Scientific Antaris family of FT-NIR analyzers and Siemens' SIPATT software platform to provide a comprehensive solution for advanced process understanding and continuous control and improvement in drug development and manufacture.

The integration is a natural extension of the Antaris analyzer product line and is designed to allow pharmaceutical companies to further extend the capabilities of the FT-NIR analyzers to achieve better process insight, real-time product release, improved manufacturing performance and enhanced quality while maintaining regulatory compliance. This initiative creates a solution tailor-made to the needs of the pharmaceutical industry that seamlessly migrates process analysis from the laboratory into production, effectively mitigating risk and is intended to drive significant
cost-savings.

All of the Antaris FT-NIR analyzers are built from the ground up to suit the specific requirements of the pharmaceutical industry. They include internal calibration standards which allow instrument qualification without having to stop the process or remove the probe from the culture media. With features like a flex-pivot interferometer and pinned-in-place optics inherent in the analyzers, each scan of the samples is the same as the last one providing accurate, precise and reliable measurements.

SIPAT is Siemens' software that supports PAT implementation, acquiring data from multiple analyzers and other data sources. SIPAT enables process understanding and continuous process improvement in both manufacturing and development. It also supports (advanced) process control whereby it can either focus on specific units or cover total batch quality to enable real-time product release. SIPAT facilitates improved and faster product development and shortens time-to-market.

What are your comments?

Join the discussion today. Login Here.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments